Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,409 across all filing types
Latest filing 2017-04-07 Share Issue/Capital Cha…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
CP en français
Share Issue/Capital Change Classification · 98% confidence The document explicitly states it is publishing the 'NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE' (New number of shares and voting rights) as of a specific date (April 4, 2017), referencing French commercial code (Code de Commerce) and AMF regulations (Autorité des marchés financiers). This content directly relates to changes in the company's capital structure and share count, which aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). Although it involves voting rights, the core announcement is the total share count, making SHA the most precise fit over DVA (which focuses on voting results) or CAP (which focuses on financing activities). The document is a formal announcement/press release, not a lengthy report, but the subject matter is specific enough to avoid the general RPA/RNS fallback.
2017-04-07 French
PR in English
Share Issue/Capital Change Classification · 95% confidence The document is titled "NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT APRIL 4, 2017" and explicitly states the total number of shares and voting rights as required by French regulations (Code de Commerce and AMF charter). This type of mandatory disclosure regarding the capital structure and voting rights is a specific regulatory announcement. It is not a full Annual Report (10-K), an Earnings Release (ER), or a comprehensive Interim Report (IR). It is a specific notification about the current share count, which aligns best with a general regulatory filing or a specific capital/share structure update. Given the options, it is a specific notification about the number of shares and voting rights, which is a form of capital structure information. However, it is not a declaration of voting results (DVA) nor a general share issue (SHA). Since it is a mandatory disclosure of share count based on regulatory articles, it fits best under a general regulatory filing (RNS) or potentially a specific capital/financing update (CAP). Since it is a routine, periodic disclosure of the share count mandated by the AMF, and not a transaction (POS) or a new issue (SHA), RNS (Regulatory Filings) is the most appropriate general category for mandatory, non-financial report disclosures that don't fit elsewhere. The length (4691 chars) is substantial enough that it is the report itself, not just an announcement of a report.
2017-04-07 English
CP en français
Report Publication Announcement Classification · 99% confidence The document is titled "INNATE PHARMA : MISE À DISPOSITION DU DOCUMENT DE RÉFÉRENCE 2016" (Availability of the 2016 Reference Document). It explicitly states that the 'Document de référence 2016' (Reference Document 2016) was filed with the AMF (Autorité des Marchés Financiers) and that this document incorporates the 'rapport financier annuel 2016' (2016 annual financial report). The document itself is a short press release dated April 3, 2017, announcing the availability of the main regulatory filing (the Reference Document, which contains the annual report). According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report has been published or made available points towards a Report Publication Announcement (RPA) rather than the full report itself (10-K or AR). Since this is an announcement about the publication of a major regulatory filing (Document de Référence), RPA is the most appropriate classification.
2017-04-03 French
PR in English
Report Publication Announcement Classification · 98% confidence The document is titled "INNATE PHARMA: 2016 REFERENCE DOCUMENT MADE AVAILABLE (IN FRENCH)" and explicitly states that the "2016 Reference document was filed with the Autorités des Marchés Financiers (AMF)". A Reference Document (Document de Référence) in the French regulatory context is a comprehensive annual filing, similar in scope to a 10-K, which includes the annual financial report. However, the document itself is an announcement *about* the filing, not the filing itself. The text states the document 'was filed' and provides links to where it is available, fitting the description of announcing the publication of a report. Given the content covers the annual report and governance information, the most appropriate classification for an announcement of a major regulatory filing that contains annual information, but is itself a short announcement, is Report Publication Announcement (RPA). If RPA were not available, RNS would be a secondary choice, but RPA specifically covers the announcement of report publication.
2017-04-03 English
Extension de l'essai de Phase I/II évaluant lirilumab avec nivolumab
Regulatory Filings Classification · 95% confidence The document is a press release dated March 13, 2017, from Innate Pharma announcing an amendment to a clinical trial protocol involving Lirilumab, Nivolumab, and Ipilimumab. It details scientific updates, partnership information (with Bristol-Myers Squibb), and includes standard sections like 'À propos de l'étude', 'À propos de lirilumab', and a financial disclaimer. This format—a formal announcement of a business/scientific development via a press release—does not fit the specific regulatory filings (10-K, IR, ER, DEF 14A, etc.). It is a general corporate announcement regarding R&D progress. Since it is not a specific report (like an Earnings Release 'ER' or Interim Report 'IR') but rather an announcement of an update, and it doesn't fit other specific categories like Director's Dealing (DIRS) or Capital Change (CAP), the most appropriate general category for corporate news releases that don't fit elsewhere is 'Regulatory Filings' (RNS), which often serves as a catch-all for official company announcements not covered by other specific codes, or potentially 'LTR' if it were about legal proceedings, but here it is about clinical trials. Given the options, RNS (Regulatory Filings) is the best fit for a general, non-financial, non-governance press release about clinical trial progress.
2017-03-13 French
Expansion of Phase I/II trial evaluating lirilumab with Opdivo
Regulatory Filings Classification · 96% confidence The document is a press release dated March 13, 2017, from Innate Pharma SA, announcing an expansion of a clinical trial protocol for a drug (Lirilumab) in combination with Bristol-Myers Squibb's Opdivo. It details scientific updates, trial endpoints, and includes standard corporate boilerplate, contact information, and a disclaimer referencing the *Document de Reference* filed with the AMF (French regulator). This type of announcement, detailing scientific progress, partnership updates, and clinical trial developments, is characteristic of an Investor Presentation (IP) or a general press release that doesn't fit the strict definitions of an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). Since it is a detailed announcement intended for investors about strategy and pipeline progress, Investor Presentation (IP) is the most appropriate classification, as it often contains more substance than a simple Regulatory Filing (RNS) or Report Publication Announcement (RPA). It is not a transcript (CT), a formal financial report (IR/10-K), or a management discussion (MDA).
2017-03-13 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.